Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Trial Profile

Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs RBLO15.1(LIP)/RBLO16.1(LIP) (Primary)
  • Indications Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARE-40
  • Most Recent Events

    • 22 Jan 2018 Status changed from active, no longer recruiting to recruiting.
    • 27 Sep 2017 New source identified and integrated European Clinical Trials Database (EudraCT2014-002061-30).
    • 26 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top